急性心肌梗死及短期应用降脂药对PCSK9的影响
|
摘要
背景：前蛋白转化酶枯草溶菌素9(proprotein convertase, subtilisin/kexin type9, PCSK9)在低密度脂蛋白受体(low density lipoprotein receptor, LDLR)的代谢过程中起着重要的作用,因而间接影响到低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)水平。目前的研究已经证实,PCSK9功能获得突变可以急剧升高LDL-C水平,导致常染色体显性高胆固醇血症(autosomal dominant hypercholesterolemia, ADH)而PCSK9功能丢失突变能够降低血清LDL-C水平,降低冠心病(coronary artery disease, CAD)的发病风险；也有研究表明CAD患者中PCSK9水平升高会增加远期心血管事件的风险。因此,降低PCSK9水平从而实现对LDL-C水平的调控,是降脂治疗的新靶点。然而,在实现对PCSK9进行调控之前,有必要深入了解影响和调节PCSK9水平的因素,因为这是针对PCSK9治疗的前提和基础。研究表明PCSK9水平受到年龄,性别,饮食状态,激素水平等的调控。急性心肌梗死(acute myocardial infarction, AMI)是CAD最为严重的表现形式,其中伴随一系列病理生理改变,包括急性期反应,炎性细胞的激活和细胞因子的释放,血脂水平的改变。然而,作为调节血脂代谢的重要蛋白之一,PCSK9在AMI中的变化却鲜为人知,因此有必要探讨AMI对PCSK9的影响。此外,Krueppel样因子2(Krueppel-like factor2, KLF2)具有保护血管内皮和抗炎作用；有研究表明在动脉粥样硬化的患者中KLF2的表达量是降低的,但尚无研究报道在急性心肌梗死的情况下该因子的表达水平。
目的：基于上述研究现状,本课题拟研究AMI情况下PCSK9水平的变化及其机制,PCSK9与血脂指标和炎症标记物的关系；同时探讨急性心肌梗死患者中KLF2的表达情况。
方法：本研究分为临床研究和动物实验两部分。临床研究部分采用病例对照设计,由对照组(n=27),稳定型冠心病组(SCAD组,n=82)和AMI组(n=33)构成。AMI组患者从发病至就诊的时间间隔为≤12小时。抽取研究对象静脉血检测PCSK9,血脂指标和炎症标记物；利用淋巴细胞分离液分离外周血单个核细胞,提取RNA,进行荧光定量PCR测定外周血单个核细胞KLF2的表达。动物实验部分利用SD大鼠,通过结扎左冠状动脉前降支构建AMI模型,分别于手术后1小时,3小时,6小时,9小时,12小时和24小时处死大鼠,留取血标本和肝脏组织。血标本进行PCSK9,血脂指标的测定；肝脏组织提取RNA,进行荧光定量PCR,测定肝脏中PCSK9和调节PCSK9表达的核转录因子——固醇调节元件结合蛋白-2(sterol regulatory element-binding protein-2, SREBP-2)和肝细胞核因子1-a (hepatocyte nuclear factor1-α, HNF1-α)的表达。此外,同时测定受到SREBF-2调控的LDLR的表达。
结果：AMI患者从发病至就诊时间的中位数为7小时。与对照组(340.56±77.62ng/mL)和SCAD组(334.99±85.96ng/mL)相比,AMI患者(290.42±79.05ng/mL) PCSK9水平明显降低(P值分别为0.01,0.02)。与对照组[中位数(第25及第75分位数)：0.37(0.30,0.46)]和SCAD组[0.39(0.32,0.5)]相比,AMI患者的FFA水平[0.5(0.41,0.72)]显著增高(P值均小于0.01)。AMI患者PCSK9与FFA呈负相关(r=-0.505,P=0.003),与其他血脂指标和炎症标记物无相关性。与对照组(4.50±5.70)和SCAD组(6.02±8.94)相比,AMI患者KLF2表达(2.81±0.92)无明显变化。动物实验结果显示AMI后早期(1小时至3小时)大鼠血清PCSK9的水平略有上升,随之下降(6小时至9小时),至12小时后上升,然后降低。荧光定量PCR结果发现AMI梗死12小时和24小时后PCSK9和LDLR mRNA升高；SREBP-2mRNA在AMI后24小时升高,而HNF1-α mRNA在AMI后6小时升高,12小时较假手术组无明显改变,24小时高于假手术组。
结论：(1)AMI患者伴随PCSK9水平的升高,其表达的上调与核转录因子SREBP-2和HNF1-α有关；并且HNF1-α介导了早期(12小时内)PCSK9的升高而SREBP-2发挥作用主要在晚期(12小时之后)。(2)AMI状态下,PCSK9水平与FFA水平存在负相关,与其他血脂指标及炎症指标无相关性。(3)AMI发病过程中不伴有KLF2表达的变化。
背景：他汀是目前降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)水平最为有效的治疗药物,是冠心病(coronary artery disease, CAD)—级和二级预防的基石。然而,增大他汀的剂量却并没有带来相应的LDL-C水平下降,长期以来,背后的原因并不清楚,直到近年发现他汀在降低LDL-C水平的同时,也升高了前蛋白转化酶枯草溶菌素9(proprotein convertase, subtilisin/kexin type9, PCSK9)的水平,而后者可以通过促进低密度脂蛋白受体(low density lipoprotein receptor, LDLR)的降解而减少LDL-C的清除,因而影响了他汀降脂的治疗效果。虽然临床研究表明他汀治疗4周或者更长时间均能升高PCSK9水平,但是有关短期应用他汀对PCSK9水平的影响却没有报道。依折麦布作为临床上广泛使用的另一类降脂药,在单独用药和与他汀联合用药降低LDL-C水平方面发挥着重要作用。然而,依折麦布是否也会对PCSK9水平有影响,目前的研究很少,且为横断面设计,缺少前瞻性随机对照试验的研究；关于依折麦布跟他汀联合用药对PCSK9的影响也无前瞻性研究。
目的：基于上述研究现状,本课题拟研究(1)短期应用他汀,依折麦布及联合应用他汀和依折麦布对PCSK9水平的影响；(2)影响降脂药治疗后PCSK9水平变化的因素；(3)患者临床特征,血脂指标及超敏C-反应蛋白(high sensitive C-reactive protein, hs-CRP)与基线PCSK9的关系
方法：本研究由两部分组成,第一部分纳入9例血脂异常的患者,给予匹伐他汀2mg/天治疗3天；第二部分纳入45例血脂异常患者,随机分为3组,分别给予依折麦布10mg/天(n=15),血脂康1200mg/天(n-15),依折麦布10mg/天+血脂康1200mg/天治疗3天(n=15)。分别于用药前和用药后第2天和第4天采血检测血清血脂指标,hs-CRP和PCSK9的浓度。采用spearman相关分析患者临床特征,血脂指标和hs-CRP与基线PCSK9的关系；采用多元线性逐步回归模型,分析患者临床特征,血脂指标,hs-CRP以及治疗药物对PCSK9治疗后变化百分率的影响。
结果：匹伐他汀用药1天和3天分别升高了PCSK941%和27%(与用药前相比,P值均<0.05)；依折麦布用药1天和3天分别升高了PCSK929%和39%(与用药前相比,P值均<0.05)；血脂康用药1天和3天分别升高了PCSK932%和55%(与用药前相比,P值均<0.05)；依折麦布+血脂康用药1天和3天分别升高了PCSK936%和41%(与用药前相比,P值分别为<0.05和>0.05)。与单独用药相比,依折麦布+血脂康没有带来额外的PCSK9升高。LDL-C (r=0.356,P=0.008),总胆固醇(total cholesterol, TC)(r=0.376, P=0.005),高密度脂蛋白胆固醇(high density lipoprotein cholesterol, HDL-C)(r=0.283, P=0.038)和hs-CRP (r=0.334, P=0.014)与基线PCSK9水平呈正相关。多元线性回归显示,治疗前的LDL-C(p=-22.444,P=0.006)和甘油三酯(triglyceride, TG)(β=14.734, P=0.031)水平影响治疗后PCSK9变化百分率。
结论：(1)匹伐他汀,依折麦布,血脂康以及依折麦布血脂康联合应用均可以在短期内升高PCSK9水平；与较单独用药相比,依折麦布血脂康联合用药并没有额外升高PCSK9水平。(2)基线LDL-C和TG水平可以预测降脂药治疗后PCSK9升高的幅度。(3)基线PCSK9水平与LDL-C, TC, HDL-C和hs-CRP呈正相关。
Background:Proprotein convertase, subtilisin/kexin type9(PCSK9) plays an important role in the metabolism of low density lipoprotein receptor (LDLR) and hence indirectly impacts the low density lipoprotein cholesterol (LDL-C) levels. It had been proved that the PCSK9gain-of-function mutations could sharply increase the LDL-C levels and cause autosomal dominant hypercholesterolemia (ADH) while PCSK9loss-of-function mutations could decrease the LDL-C levels and associate with lower risk of coronary artery disease (CAD). Besides, study also indicated that CAD patients with high PCSK9levels were at high risk of long-term cardiovascular events. Hence, lowering PCSK9levels was the new target of managing the LDL-C levels. However, it is necessary to fully understand the regulatory factors involved in PCSK9before the manipulating of PCSK9, which is the foundation of forming a therapy targeting PCSK9. Studies had suggested that PCSK9levels were regulated by other factors such as age, gender, the status of dietary, and hormone. Acute myocardial infarction (AMI), the most severe form of CAD, was associated with a series of pathophysiological changes, including acute phase reaction, activation of inflammatory cells and release of cytokine, and changes in lipid levels. However, as one of the most important protein involved in lipid homeostasis, the change of PCSK9in the circumstance of AMI is unclear. Therefore it is necessary to explore its fluctuation in levels under AMI. In addition, studies had proved the endothelial protective and anti-inflammatory role of Krueppel-like factor2(KLF2) and its decreased levels were observed in patients with atherosclerosis. However, no study exists reporting its levels in AMI.
Objective:Based on the aforementioned background, the present study was aimed to explore the change in PCSK9levels in AMI and the mechanisms behind it, the correlation between PCSK9and lipid parameters as well as inflammatory biomarkers, and the expression of KLF2under AMI.
Methods:The present study consisted of clinical and animal parts. The clinical part used a case-control design, which included control group (n=27), stable coronary artery disease (SCAD) group (n=82), and AMI group (n=33). For patients with AMI, the time between symptom onset and hospital admission was less than12hours. Venous blood was drawn for all participants and PCSK9, lipid parameters and inflammatory biomarkers were measured. Peripheral blood mononuclear cells were isolated with Ficoll-Hypaque, their RNA was extracted and real time quantitative polymerase chain reaction (PCR) was used to measure the expression of KLF2. The animal part was conducted with SD rats. AMI model was constructed by ligation of the left anterior descending (LAD) branch of the coronary artery. The rats were killed at1,3,6,9,12, and24hours after the ligation of LAD, and blood samples and liver tissue were collected. The blood samples were used for the test of PCSK9and lipid parameters while liver tissue was used for RNA extraction. Real time quantitative PCR was performed to assay the expression of PCSK9and its regulatory nuclear transcription factors——(sterol regulatory element-binding protein-2, SREBP-2) and hepatocyte nuclear factorl-a (HNF1-α). In addition, the expression of LDLR, another target gene of SREBP-2, was also assayed.
Results:The median time between symptom onset and hospital admission was7hours. Plasma levels of PCSK9were significantly lower in patients with AMI (290.42±79.05ng/ml) compared with those with SCAD (334.99±85.96ng/ml, P=0.01) and control subjects (340.56±77.62ng/ml, P=0.02). Plasma levels of free fatty acid (FFA) were significantly higher in patients with AMI [median (interquartile range):0.5(0.41,0.72)] compared with those with SCAD [0.37(0.30,0.46)] and control subjects [0.39(0.32,0.5)](both P<0.05). For patients with AMI, PCSK9levels were negatively correlated with FFA levels (r=-0.505, P=0.003), but no other association of other lipid parameters and inflammatory biomarkers with PCSK9was found. There was no significant difference in the relative expression of KLF2among patients with AMI (2.81±0.92), SCAD (6.02±8.94), and control subjects(4.50±5.70). The findings in animal experiment indicated that the levels of PCSK9slightly increased in the early stage (1-3hours) of AMI, followed by a decrease at6-9hours, an increase at12hours, and a decrease thereafter. Real time quantitative PCR results showed that the mRNA expression of PCSK9and LDLR increased at12and24hours after AMI and that SREBF-2mRNA increased at24hours after AMI, whereas HNF1-α mRNA increased at6hours after AMI with no significant change at12hours and increased levels at24hours when compared with sham group.
Conclusion:(1) AMI was accompanied with high levels of PCSK9, the increased expression of which was mediated through SREBP-2and HNF1-α. The early (within12hours) up-regulation of PCSK9was mediated via HNF1-α whereas its late (after12hours) up-regulation was mediated via SREBP-2.(2) Under the circumstance of AMI, PCSK9levels was negatively correlated with FFA and on correlation exited between PCSK9and other lipid parameters and inflammatory biomarkers.(3) During the process of AMI, there was no significant change in the expression of KLF2.
Background:Since statins are the most effective drugs used for lowering low density lipoprotein cholesterol (LDL-C), they are the cornerstone of the first and second prevention in coronary artery disease thus far. It had been observed for a long time that an increase in the dose of statins did not bring appropriate decrease in LDL-C. The mechanism behind this phenomenon was not clear until the findings that statins increase the levels of proprotein convertase, subtilisin/kexin type9(PCSK9) when decreasing the levels of LDL-C and PCSK9could promote the degradation of low density lipoprotein receptor (LDLR), which in turn negated the lipid-lowering effects of statins. Although clinical studies had proved that statin therapy for4weeks or longer would increase the levels of PCSK9, the short-term impact of statins on PCSK9has not been reported. Besides, ezetimibe, another class of lipid-lowering drug, which had also been widely used in clinical practice, plays a pivotal role in lowering LDL-C when in monotherapy or in combination with statins. However, studies concerning the impact of ezetimibe on PCSK9were limited and those published are cross-section design, hence there is a lack of prospective, random control study. In addition, no study exists reporting the impact on PCKS9of combination of ezetimibe and statin.
Objective:Based on the aforementioned background, the present study was to investigate (1) the impacts on PCSK9of short-term statin, ezetimibe and the combined therapy of both drugs;(2) the factors associated with the percent change in PCSK9after lipid-lowering drugs therapy; and (3) the association of the clinical characteristics of patients, lipid parameters and high sensitive C-reactive protein (hs-CRP) with baseline PCSK9levels.
Methods:The present study consisted of two parts with the first enrolling9patients with dyslipidemia and the second enrolling45patients with dyslipidemia. The patients in the first part were given pitavastatin2mg daily for three days, and those in the second part were evenly randomized into the following three groups:(1) ezetimibe group (ezetimibe10mg daily for three days);(2)xuezhikang group (xuezhikang1200mg daily for three days); and (3) combination group (ezetimibe10mg daily plus xuezhikang1200mg daily for three days). Fasting blood samples were collected before therapy and on the second and fourth day after the administration of drugs and the concentrations of lipid parameters, hs-CRP, and PCSK9in serum were measured. Spearman correlation analyses were performed to examine the association of the clinical characteristics of patients, lipid parameters and hs-CRP with PCSK9. Multivariate linear stepwise regression was used to explore the impacts on percent change in PCSK9of the characteristics of patients, lipid parameters, hs-CRP and drugs.
Results:Pitavastatin increased PCSK9levels by41%at day1and27%at day3(both p<0.05compared with day0); ezetimibe increased PCSK9levels by29%at day1and39%at day3(both p<0.05compared with day0); xuezhikang increased PCSK9levels by32%at day1and55%at day3(both p<0.05compared with day0); ezetimibe plus xuezhikang increased PCSK9levels by36%at day1(p<0.05compared with day0) and41%(p>0.05compared with day0) at day3. LDL-C (r=0.356, P=0.008), total cholesterol (TC, r=0.376, P=0.005), high density lipoprotein cholesterol (HDL-C, r=0.283, P=0.038), and hs-CRP (r=0.334, P=0.014) were positively correlated with the baseline PCSK9levels. Multivariate linear regression indicated that baseline LDL-C (β=-22.444, P=0.006) and triglyceride (TG,β=14.734, P=0.031) levels were predictors of percent change in PCSK9after therapy.
Conclusion:(1) Pitavastatin, ezetimibe, xuezhikang and the combination of ezetimibe and xuezhikang could increase PCSK9levels in short-term and combination of ezetimibe and xuezhikang did not result in greater increase in PCSK9compared to the monotherapy with either agent.(2) Baseline LDL-C and TG levels were predictors of percent change in PCSK9after therapy.(3) Baseline PCSK9levels were positively correlated with LDL-C, TC, HDL-C, and hs-CRP.
目的：基于上述研究现状,本课题拟研究AMI情况下PCSK9水平的变化及其机制,PCSK9与血脂指标和炎症标记物的关系；同时探讨急性心肌梗死患者中KLF2的表达情况。
方法：本研究分为临床研究和动物实验两部分。临床研究部分采用病例对照设计,由对照组(n=27),稳定型冠心病组(SCAD组,n=82)和AMI组(n=33)构成。AMI组患者从发病至就诊的时间间隔为≤12小时。抽取研究对象静脉血检测PCSK9,血脂指标和炎症标记物；利用淋巴细胞分离液分离外周血单个核细胞,提取RNA,进行荧光定量PCR测定外周血单个核细胞KLF2的表达。动物实验部分利用SD大鼠,通过结扎左冠状动脉前降支构建AMI模型,分别于手术后1小时,3小时,6小时,9小时,12小时和24小时处死大鼠,留取血标本和肝脏组织。血标本进行PCSK9,血脂指标的测定；肝脏组织提取RNA,进行荧光定量PCR,测定肝脏中PCSK9和调节PCSK9表达的核转录因子——固醇调节元件结合蛋白-2(sterol regulatory element-binding protein-2, SREBP-2)和肝细胞核因子1-a (hepatocyte nuclear factor1-α, HNF1-α)的表达。此外,同时测定受到SREBF-2调控的LDLR的表达。
结果：AMI患者从发病至就诊时间的中位数为7小时。与对照组(340.56±77.62ng/mL)和SCAD组(334.99±85.96ng/mL)相比,AMI患者(290.42±79.05ng/mL) PCSK9水平明显降低(P值分别为0.01,0.02)。与对照组[中位数(第25及第75分位数)：0.37(0.30,0.46)]和SCAD组[0.39(0.32,0.5)]相比,AMI患者的FFA水平[0.5(0.41,0.72)]显著增高(P值均小于0.01)。AMI患者PCSK9与FFA呈负相关(r=-0.505,P=0.003),与其他血脂指标和炎症标记物无相关性。与对照组(4.50±5.70)和SCAD组(6.02±8.94)相比,AMI患者KLF2表达(2.81±0.92)无明显变化。动物实验结果显示AMI后早期(1小时至3小时)大鼠血清PCSK9的水平略有上升,随之下降(6小时至9小时),至12小时后上升,然后降低。荧光定量PCR结果发现AMI梗死12小时和24小时后PCSK9和LDLR mRNA升高；SREBP-2mRNA在AMI后24小时升高,而HNF1-α mRNA在AMI后6小时升高,12小时较假手术组无明显改变,24小时高于假手术组。
结论：(1)AMI患者伴随PCSK9水平的升高,其表达的上调与核转录因子SREBP-2和HNF1-α有关；并且HNF1-α介导了早期(12小时内)PCSK9的升高而SREBP-2发挥作用主要在晚期(12小时之后)。(2)AMI状态下,PCSK9水平与FFA水平存在负相关,与其他血脂指标及炎症指标无相关性。(3)AMI发病过程中不伴有KLF2表达的变化。
背景：他汀是目前降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)水平最为有效的治疗药物,是冠心病(coronary artery disease, CAD)—级和二级预防的基石。然而,增大他汀的剂量却并没有带来相应的LDL-C水平下降,长期以来,背后的原因并不清楚,直到近年发现他汀在降低LDL-C水平的同时,也升高了前蛋白转化酶枯草溶菌素9(proprotein convertase, subtilisin/kexin type9, PCSK9)的水平,而后者可以通过促进低密度脂蛋白受体(low density lipoprotein receptor, LDLR)的降解而减少LDL-C的清除,因而影响了他汀降脂的治疗效果。虽然临床研究表明他汀治疗4周或者更长时间均能升高PCSK9水平,但是有关短期应用他汀对PCSK9水平的影响却没有报道。依折麦布作为临床上广泛使用的另一类降脂药,在单独用药和与他汀联合用药降低LDL-C水平方面发挥着重要作用。然而,依折麦布是否也会对PCSK9水平有影响,目前的研究很少,且为横断面设计,缺少前瞻性随机对照试验的研究；关于依折麦布跟他汀联合用药对PCSK9的影响也无前瞻性研究。
目的：基于上述研究现状,本课题拟研究(1)短期应用他汀,依折麦布及联合应用他汀和依折麦布对PCSK9水平的影响；(2)影响降脂药治疗后PCSK9水平变化的因素；(3)患者临床特征,血脂指标及超敏C-反应蛋白(high sensitive C-reactive protein, hs-CRP)与基线PCSK9的关系
方法：本研究由两部分组成,第一部分纳入9例血脂异常的患者,给予匹伐他汀2mg/天治疗3天；第二部分纳入45例血脂异常患者,随机分为3组,分别给予依折麦布10mg/天(n=15),血脂康1200mg/天(n-15),依折麦布10mg/天+血脂康1200mg/天治疗3天(n=15)。分别于用药前和用药后第2天和第4天采血检测血清血脂指标,hs-CRP和PCSK9的浓度。采用spearman相关分析患者临床特征,血脂指标和hs-CRP与基线PCSK9的关系；采用多元线性逐步回归模型,分析患者临床特征,血脂指标,hs-CRP以及治疗药物对PCSK9治疗后变化百分率的影响。
结果：匹伐他汀用药1天和3天分别升高了PCSK941%和27%(与用药前相比,P值均<0.05)；依折麦布用药1天和3天分别升高了PCSK929%和39%(与用药前相比,P值均<0.05)；血脂康用药1天和3天分别升高了PCSK932%和55%(与用药前相比,P值均<0.05)；依折麦布+血脂康用药1天和3天分别升高了PCSK936%和41%(与用药前相比,P值分别为<0.05和>0.05)。与单独用药相比,依折麦布+血脂康没有带来额外的PCSK9升高。LDL-C (r=0.356,P=0.008),总胆固醇(total cholesterol, TC)(r=0.376, P=0.005),高密度脂蛋白胆固醇(high density lipoprotein cholesterol, HDL-C)(r=0.283, P=0.038)和hs-CRP (r=0.334, P=0.014)与基线PCSK9水平呈正相关。多元线性回归显示,治疗前的LDL-C(p=-22.444,P=0.006)和甘油三酯(triglyceride, TG)(β=14.734, P=0.031)水平影响治疗后PCSK9变化百分率。
结论：(1)匹伐他汀,依折麦布,血脂康以及依折麦布血脂康联合应用均可以在短期内升高PCSK9水平；与较单独用药相比,依折麦布血脂康联合用药并没有额外升高PCSK9水平。(2)基线LDL-C和TG水平可以预测降脂药治疗后PCSK9升高的幅度。(3)基线PCSK9水平与LDL-C, TC, HDL-C和hs-CRP呈正相关。
Background:Proprotein convertase, subtilisin/kexin type9(PCSK9) plays an important role in the metabolism of low density lipoprotein receptor (LDLR) and hence indirectly impacts the low density lipoprotein cholesterol (LDL-C) levels. It had been proved that the PCSK9gain-of-function mutations could sharply increase the LDL-C levels and cause autosomal dominant hypercholesterolemia (ADH) while PCSK9loss-of-function mutations could decrease the LDL-C levels and associate with lower risk of coronary artery disease (CAD). Besides, study also indicated that CAD patients with high PCSK9levels were at high risk of long-term cardiovascular events. Hence, lowering PCSK9levels was the new target of managing the LDL-C levels. However, it is necessary to fully understand the regulatory factors involved in PCSK9before the manipulating of PCSK9, which is the foundation of forming a therapy targeting PCSK9. Studies had suggested that PCSK9levels were regulated by other factors such as age, gender, the status of dietary, and hormone. Acute myocardial infarction (AMI), the most severe form of CAD, was associated with a series of pathophysiological changes, including acute phase reaction, activation of inflammatory cells and release of cytokine, and changes in lipid levels. However, as one of the most important protein involved in lipid homeostasis, the change of PCSK9in the circumstance of AMI is unclear. Therefore it is necessary to explore its fluctuation in levels under AMI. In addition, studies had proved the endothelial protective and anti-inflammatory role of Krueppel-like factor2(KLF2) and its decreased levels were observed in patients with atherosclerosis. However, no study exists reporting its levels in AMI.
Objective:Based on the aforementioned background, the present study was aimed to explore the change in PCSK9levels in AMI and the mechanisms behind it, the correlation between PCSK9and lipid parameters as well as inflammatory biomarkers, and the expression of KLF2under AMI.
Methods:The present study consisted of clinical and animal parts. The clinical part used a case-control design, which included control group (n=27), stable coronary artery disease (SCAD) group (n=82), and AMI group (n=33). For patients with AMI, the time between symptom onset and hospital admission was less than12hours. Venous blood was drawn for all participants and PCSK9, lipid parameters and inflammatory biomarkers were measured. Peripheral blood mononuclear cells were isolated with Ficoll-Hypaque, their RNA was extracted and real time quantitative polymerase chain reaction (PCR) was used to measure the expression of KLF2. The animal part was conducted with SD rats. AMI model was constructed by ligation of the left anterior descending (LAD) branch of the coronary artery. The rats were killed at1,3,6,9,12, and24hours after the ligation of LAD, and blood samples and liver tissue were collected. The blood samples were used for the test of PCSK9and lipid parameters while liver tissue was used for RNA extraction. Real time quantitative PCR was performed to assay the expression of PCSK9and its regulatory nuclear transcription factors——(sterol regulatory element-binding protein-2, SREBP-2) and hepatocyte nuclear factorl-a (HNF1-α). In addition, the expression of LDLR, another target gene of SREBP-2, was also assayed.
Results:The median time between symptom onset and hospital admission was7hours. Plasma levels of PCSK9were significantly lower in patients with AMI (290.42±79.05ng/ml) compared with those with SCAD (334.99±85.96ng/ml, P=0.01) and control subjects (340.56±77.62ng/ml, P=0.02). Plasma levels of free fatty acid (FFA) were significantly higher in patients with AMI [median (interquartile range):0.5(0.41,0.72)] compared with those with SCAD [0.37(0.30,0.46)] and control subjects [0.39(0.32,0.5)](both P<0.05). For patients with AMI, PCSK9levels were negatively correlated with FFA levels (r=-0.505, P=0.003), but no other association of other lipid parameters and inflammatory biomarkers with PCSK9was found. There was no significant difference in the relative expression of KLF2among patients with AMI (2.81±0.92), SCAD (6.02±8.94), and control subjects(4.50±5.70). The findings in animal experiment indicated that the levels of PCSK9slightly increased in the early stage (1-3hours) of AMI, followed by a decrease at6-9hours, an increase at12hours, and a decrease thereafter. Real time quantitative PCR results showed that the mRNA expression of PCSK9and LDLR increased at12and24hours after AMI and that SREBF-2mRNA increased at24hours after AMI, whereas HNF1-α mRNA increased at6hours after AMI with no significant change at12hours and increased levels at24hours when compared with sham group.
Conclusion:(1) AMI was accompanied with high levels of PCSK9, the increased expression of which was mediated through SREBP-2and HNF1-α. The early (within12hours) up-regulation of PCSK9was mediated via HNF1-α whereas its late (after12hours) up-regulation was mediated via SREBP-2.(2) Under the circumstance of AMI, PCSK9levels was negatively correlated with FFA and on correlation exited between PCSK9and other lipid parameters and inflammatory biomarkers.(3) During the process of AMI, there was no significant change in the expression of KLF2.
Background:Since statins are the most effective drugs used for lowering low density lipoprotein cholesterol (LDL-C), they are the cornerstone of the first and second prevention in coronary artery disease thus far. It had been observed for a long time that an increase in the dose of statins did not bring appropriate decrease in LDL-C. The mechanism behind this phenomenon was not clear until the findings that statins increase the levels of proprotein convertase, subtilisin/kexin type9(PCSK9) when decreasing the levels of LDL-C and PCSK9could promote the degradation of low density lipoprotein receptor (LDLR), which in turn negated the lipid-lowering effects of statins. Although clinical studies had proved that statin therapy for4weeks or longer would increase the levels of PCSK9, the short-term impact of statins on PCSK9has not been reported. Besides, ezetimibe, another class of lipid-lowering drug, which had also been widely used in clinical practice, plays a pivotal role in lowering LDL-C when in monotherapy or in combination with statins. However, studies concerning the impact of ezetimibe on PCSK9were limited and those published are cross-section design, hence there is a lack of prospective, random control study. In addition, no study exists reporting the impact on PCKS9of combination of ezetimibe and statin.
Objective:Based on the aforementioned background, the present study was to investigate (1) the impacts on PCSK9of short-term statin, ezetimibe and the combined therapy of both drugs;(2) the factors associated with the percent change in PCSK9after lipid-lowering drugs therapy; and (3) the association of the clinical characteristics of patients, lipid parameters and high sensitive C-reactive protein (hs-CRP) with baseline PCSK9levels.
Methods:The present study consisted of two parts with the first enrolling9patients with dyslipidemia and the second enrolling45patients with dyslipidemia. The patients in the first part were given pitavastatin2mg daily for three days, and those in the second part were evenly randomized into the following three groups:(1) ezetimibe group (ezetimibe10mg daily for three days);(2)xuezhikang group (xuezhikang1200mg daily for three days); and (3) combination group (ezetimibe10mg daily plus xuezhikang1200mg daily for three days). Fasting blood samples were collected before therapy and on the second and fourth day after the administration of drugs and the concentrations of lipid parameters, hs-CRP, and PCSK9in serum were measured. Spearman correlation analyses were performed to examine the association of the clinical characteristics of patients, lipid parameters and hs-CRP with PCSK9. Multivariate linear stepwise regression was used to explore the impacts on percent change in PCSK9of the characteristics of patients, lipid parameters, hs-CRP and drugs.
Results:Pitavastatin increased PCSK9levels by41%at day1and27%at day3(both p<0.05compared with day0); ezetimibe increased PCSK9levels by29%at day1and39%at day3(both p<0.05compared with day0); xuezhikang increased PCSK9levels by32%at day1and55%at day3(both p<0.05compared with day0); ezetimibe plus xuezhikang increased PCSK9levels by36%at day1(p<0.05compared with day0) and41%(p>0.05compared with day0) at day3. LDL-C (r=0.356, P=0.008), total cholesterol (TC, r=0.376, P=0.005), high density lipoprotein cholesterol (HDL-C, r=0.283, P=0.038), and hs-CRP (r=0.334, P=0.014) were positively correlated with the baseline PCSK9levels. Multivariate linear regression indicated that baseline LDL-C (β=-22.444, P=0.006) and triglyceride (TG,β=14.734, P=0.031) levels were predictors of percent change in PCSK9after therapy.
Conclusion:(1) Pitavastatin, ezetimibe, xuezhikang and the combination of ezetimibe and xuezhikang could increase PCSK9levels in short-term and combination of ezetimibe and xuezhikang did not result in greater increase in PCSK9compared to the monotherapy with either agent.(2) Baseline LDL-C and TG levels were predictors of percent change in PCSK9after therapy.(3) Baseline PCSK9levels were positively correlated with LDL-C, TC, HDL-C, and hs-CRP.
引文
[1]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
[2]Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1448-53.
[3]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[4]Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response. Arterioscler Thromb Vase Biol 2005;25:2654-60.
[5]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9.
[6]Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
[7]Scartezini M, Hubbart C, Whittall RA, et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clinical Science 2007; 113:435-41.
[8]Huang C-C, Fornage M, Lloyd-Jones DM, et al. Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study. Circulation: Cardiovascular Genetics 2009;2:354-61.
[9]Berge KE, Ose L and Leren TP. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:1094-100. [10] Miyake Y, Kimura R, Kokubo Y, et al. Genetic variants in PCSK9 in the Japanese population:Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008; 196:29-36.
[11]Bourbon M, Alves AC, Medeiros AM, et al. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008; 196:633-42.
[12]Norata GD, Garlaschelli K, Grigore L, et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177-82.
[13]Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007;2:e1043.
[14]Maxwell KN and Breslow JL. Adeno viral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004;101:7100-5.
[15]Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. The Journal of Clinical Investigation 2006; 116:2995-3005.
[16]Zhang D-W, Lagace TA, Garuti R, et al. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry 2007;282:18602-12.
[17]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009;284:1313-23.
[18]Persson L, Cao G, Stahle L, et al. Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2010;32:2666-72.
[19]Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry 2006;281:6211-8.
[20]Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010;213:632-6.
[21]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[22]Libby P, Ridker PM, Hansson GK, et al. Inflammation in Atherosclerosis:From Pathophysiology to Practice. J Am Coll Cardiol 2009;54:2129-38.
[23]Galkina E and Ley K. Immune and Inflammatory Mechanisms of Atherosclerosis*. Annual Review of Immunology 2009;27:165-97.
[24]Gui MH, Hong J, Lu AK, et al. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status. Chin Med J (Engl) 2008; 121:2509-16.
[25]Pacilli A, De Cosmo S, Trischitta V, et al. Role of relationship between HbAlc, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. Atherosclerosis 2013.
[26]Okada K, Furusyo N, Murata M, et al. A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance. Endocrine 2012;41:96-102.
[27]Vaverkova H, Karasek D, Novotny D, et al. Apolipoprotein B versus LDL-cholesterol:Association with other risk factors for atherosclerosis. Clin Biochem 2009;42:1246-51.
[28]Baker RG, Hayden MS and Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22.
[29]Chen XL, Dodd G, Thomas S, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006;290:H1862-70.
[30]He X, Kan H, Cai L, et al. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 2009;46:47-58.
[31]Muthusamy VR, Kannan S, Sadhaasivam K, et al. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med 2012;52:366-76.
[32]Feinberg MW, Lin Z, Fisch S, et al. An Emerging Role for Kruppel-Like Factors in Vascular Biology. Trends in Cardiovascular Medicine 2004; 14:241-6.
[33]SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199:1305-15.
[34]Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proceedings of the National Academy of Sciences 2006;103:6653-8.
[35]Fresco C, Maggioni AP, Signorini S, et al. Variations in lipoprotein levels after myocardial infarction and unstable angina:the LATIN trial. Ital Heart J 2002;3:587-92.
[36]Pitt B, Loscalzo J, Ycas J, et al. Lipid Levels After Acute Coronary Syndromes. Journal of the American College of Cardiology 2008;51:1440-5.
[37]Balci B. The modification of serum lipids after acute coronary syndrome and importance in clinical practice. Curr Cardiol Rev 2011;7:272-6.
[38]Husain M, Armstrong PW, Connelly PW, et al. Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction. Can J Cardiol 1995;11:206-10.
[39]Oliver MF, Kurien VA and Greenwood TW. Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1968;1:710-4.
[40]Kurien VA and Oliver MF. Free fatty acids during acute myocardial infarction. Prog Cardiovasc Dis 1971;13:361-73.
[41]Oliver MF. Free fatty acids and acute coronary syndromes-the history. QJM 2011;104:625-7.
[42]Byrne C, Fitzgerald A, Cannon C, et al. Elevated white cell count in acute coronary syndromes:relationship to variants in inflammatory and thrombotic genes. BMC Medical Genetics 2004;5:13.
[43]Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI16 Investigators. Am J Cardiol 2001;87:636-9, A10.
[44]Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction:a thrornbolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.
[45]Yip HK, Wu CJ, Chang HW, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004;126:1417-22.
[46]Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome:Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. International Journal of Cardiology 2006; 109:248-56.
[47]Yip HK, Hang CL, Fang CY, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005;127:803-8.
[48]Zairis MN, Manousakis SJ, Stefanidis AS, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002;144:782-9.
[49]Thongtang N, Diffenderfer MR, Ooi EM, et al. Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism 2013;62:369-75.
[50]Takahashi T, Hiasa Y, Ohara Y, et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol 2007;100:35-40.
[51]Kaya MG, Akpek M, Lam YY, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention:A prospective, multicenter study. Int J Cardiol 2012.
[52]Bonvini RF, Hendiri T and Camenzind E. Inflammatory response post-myocardial infarction and reperfusion:a new therapeutic target? European Heart Journal Supplements 2005;7:I27-I36.
[53]Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells. Circulation 2005;112:720-6.
[54]Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res 2008;103:690-3.
[55]Lingrel JB, Pilcher-Roberts R, Basford JE, et al. Myeloid-Specific Kruppel-Like Factor 2 Inactivation Increases Macrophage and Neutrophil Adhesion and Promotes Atherosclerosis. Circulation Research 2012;110:1294-302.
[56]Dekker RJ, van Thienen JV, Rohlena J, et al. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005;167:609-18.
[57]van Thienen JV, Fledderus JO, Dekker RJ, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovascular Research 2006;72:231-40.
[58]Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-9.
[59]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009;94:2537-43.
[60]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[61]Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009;55:1637-45.
[62]Cariou B, Le Bras M, Langhi C, et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010;211:700-2.
[63]Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008;54:1038-45.
[64]Mayne J, Raymond A, Chaplin A, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007;361:451-6.
[65]Chan DC, Lambert G, Barrett PH, et al. Plasma proprotein convertase subtilisin/kexin type 9:a marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009;55:2049-52.
[66]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[67]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[68]Miyazawa H, Honda T, Miyauchi S, et al. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta 2012;413:154-9.
[69]Gallin JI, Kaye D and O'Leary WM. Serum lipids in infection. N Engl J Med 1969;281:1081-6.
[70]Kim HL, Jeon HH, Park IY, et al. Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. J Korean Med Sci 2011;26:654-8.
[71]Khovidhunkit W, Kim M-S, Memon RA, et al. Thematic review series:The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. Journal of Lipid Research 2004;45:1169-96.
[72]Dong F, Wang B, Zhang L, et al. Metabolic response to Klebsiella pneumoniae infection in an experimental rat model. PLoS One 2012;7:e51060.
[73]Feingold KR, Moser AH, Shigenaga JK, et al. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008;374:341-4.
[74]Miyazawa H, Tabeta K, Miyauchi S, et al. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice. Lipids Health Dis 2012;11:121.
[75]Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med 2012;30:931-8.
[76]Weber LW, Boll M and Stampfl A. Maintaining cholesterol homeostasis:sterol regulatory element-binding proteins. World J Gastroenterol 2004; 10:3081-7.
[77]Brown MS and Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proceedings of the National Academy of Sciences 1999;96:11041-8.
[78]Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research 2003;44:2109-19.
[79]Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003; 100:12027-32.
[80]Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24:1454-9.
[81]Kourimate S, Le May C, Langhi C, et al. Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Biological Chemistry 2008;283:9666-73.
[82]Espenshade PJ and Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 2007;41:401-27.
[83]Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000; 11 Suppl 16:S140-3.
[84]Pontoglio M, Barra J, Hadchouel M, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84:575-85.
[85]Shih DQ, Bussen M, Sehayek E, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001;27:375-82.
[86]Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to poly genie dyslipidemia. Nat Genet 2009;41:56-65.
[87]Reiner AP, Gross MD, Carlson CS, et al. Common coding variants of the HNF1A gene are associated with multiple cardiovascular risk phenotypes in community-based samples of younger and older European-American adults:the Coronary Artery Risk Development in Young Adults Study and The Cardiovascular Health Study. Circ Cardiovasc Genet 2009;2:244-54.
[88]Pramfalk C, Jiang ZY, Cai Q, et al. HNF1 alpha and SREBP2 are important regulators of NPC1L1 in human liver. J Lipid Res 2010;51:1354-62.
[89]Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95.
[90]Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction-is cholesterol a positive acute phase reactant? Atherosclerosis 1999;142:389-93.
[91]Browning JD and Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010;51:3359-63.
[92]Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
[93]de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
[94]Tsai TT, Nallamothu BK, Mukherjee D, et al. Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein≤80 mg/dl. The American Journal of Cardiology 2005;96:1491-3.
[95]Lee KH, Jeong MH, Kim HM, et al. Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 2011;58:1664-71.
[96]Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) TrialA Nested Case-Control Study. Journal of the American College of Cardiology 2012;59:1778-84.
[1]Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003; 100:928-33.
[2]Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem 2006;98:838-50.
[3]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
[4]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[5]Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-53.
[6]Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants:zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279:48865-75.
[7]Lalanne F, Lambert G, Amar MJ, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005;46:1312-9.
[8]Park SW, Moon YA and Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004;279:50630-8.
[9]Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007;48:1488-98.
[10]Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-12.
[11]McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009;284:10561-70.
[12]Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
[13]Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
[14]O'Keefe JH, Jr., Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl:lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6.
[15]Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160,ⅲ-ⅳ.
[16]Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
[17]Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression:A randomized trial in healthy men. Atherosclerosis 2008; 198:198-207.
[18]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[19]Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response:the JUPITER Trial. Clinical Chemistry 2012;58:183-9.
[20]Michelena HI, Osorio LA and Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol 2005;101:111-4.
[21]Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia:pooled analysis of two phase Ⅱ studies. Clin Ther 2001;23:1209-30.
[22]Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106:1943-8.
[23]Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.
[24]Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
[25]Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53.
[26]Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia:the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464-73.
[27]Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-73.
[28]Liu J, Luo S-H, Qing P, et al. Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro-and anti-inflammatory markers. Clinical Lipidology 2013;8:151-7.
[29]Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6.
[30]Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia:a meta-analysis of randomized controlled trials. Chin Med 2006; 1:4.
[31]Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients:a randomized trial. Ann Intern Med 2009;150:830-9, W147-9.
[32]Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105:198-204.
[33]Venero CV, Venero JV, Wortham DC, et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010;105:664-6.
[34]Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101:1689-93.
[35]Li JJ, Lu ZL, Kou WR, et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009;49:947-56.
[36]Li JJ, Lu ZL, Kou WR, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010;42:231-40.
[37]Shang Q, Liu Z, Chen K, et al. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012;2012:636547.
[38]Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24:1454-9.
[39]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[40]Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010;212:246-51.
[41]Dubuc G, Chamberland A, Wassef H, et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1454-9.
[42]Tremblay AJ, Lamarche B, Lemelin V, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Journal of Lipid Research 2011;52:558-65.
[43]Davignon J and Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163-73.
[44]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[45]Ason B, Tep S, Davis HR, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of Lipid Research 2011;52:679-87.
[46]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[47]Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-9.
[48]Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95.
[49]Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1 alpha and SREBP2:mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51:1486-95.
[50]Toniatti C, Demartis A, Monaci P, et al. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J 1990;9:4467-75.
[51]Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180:3492-501.
[1]Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):Liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences 2003;100:928-33.
[2]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
[3]Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9):Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008;48:646-54.
[4]Dewpura T, Raymond A, Hamelin J, et al. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS Journal 2008;275:3480-93.
[5]Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A:functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006;281:30561-72.
[6]Zhang D-W, Lagace TA, Garuti R, et al. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry 2007;282:18602-12.
[7]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants. Journal of Biological Chemistry 2009;284:1313-23.
[8]Lo Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011;12:1300-5.
[9]Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. The Journal of Clinical Investigation 2006; 116:2995-3005.
[10]Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences 2008;105:1820-5.
[11]Benjannet S, Luna Saavedra YG, Hamelin J, et al. Effects of the Prosegment and pH on the Activity of PCSK9:EVIDENCE FOR ADDITIONAL PROCESSING EVENTS. Journal of Biological Chemistry 2010;285:40965-78.
[12]Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents. Clinical Chemistry 2009;55:1637-45.
[13]Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010;213:632-6.
[14]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[15]Persson L, Cao G, Stahle L, et al. Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2010;32:2666-72.
[16]Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry 2006;281:6211-8.
[17]Rudenko G and Deisenhofer J. The low-density lipoprotein receptor:ligands, debates and lore. Current Opinion in Structural Biology 2003; 13:683-9.
[18]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009;284:1313-23.
[19]Pandit S, Wisniewski D, Santoro JC, et al. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. Journal of Lipid Research 2008;49:1333-43.
[20]Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-23.
[21]Cameron J, Holla OL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Human Molecular Genetics 2006; 15:1551-8.
[22]Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1448-53.
[23]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9.
[24]Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response. Arterioscler Thromb Vase Biol 2005;25:2654-60.
[25]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[26]Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012;223:394-400.
[27]Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
[28]Scartezini M, Hubbart C, Whittall RA, et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clinical Science 2007; 113:435-41.
[29]Bourbon M, Alves AC, Medeiros AM, et al. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008;196:633-42.
[30]Chen SN, Ballantyne CM, Gotto JAM, et al. A Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis. Journal of the American College of Cardiology 2005;45:1611-9.
[31]Hsu LA, Teng MS, Ko YL, et al. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin Chem Lab Med 2009;47:154-8.
[32]Norata GD, Garlaschelli K, Grigore L, et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177-82.
[33]Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007;2:e1043.
[34]Huang C-C, Fornage M, Lloyd-Jones DM, et al. Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study. Circulation: Cardiovascular Genetics 2009;2:354-61.
[35]Naoumova RP, Tosi I, Patel D, et al. Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene:Long-Term Follow-Up and Treatment Response. Arteriosclerosis, Thrombosis, and Vascular Biology 2005;25:2654-60.
[36]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. Journal of Medical Genetics 2006;43:943-9.
[37]Homer VM, Marais AD, Charlton F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008; 196:659-66.
[38]Cameron J, Holla OL, Laerdahl JK, et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. Journal of Internal Medicine 2008;263:420-31.
[39]Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Human Mutation 2005;26:497-.
[40]Essalmani R, Susan-Resiga D, Chamberland A, et al. In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. Journal of Biological Chemistry 2011;286:4257-63.
[41]Pisciotta L, Oliva CP, Cefalu AB, et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006; 186:433-40.
[42]Noguchi T, Katsuda S, Kawashiri M-a, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010;210:166-72.
[43]Berge KE, Ose L and Leren TP. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:1094-100.
[44]Miyake Y, Kimura R, Kokubo Y, et al. Genetic variants in PCSK9 in the Japanese population:Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008;196:29-36.
[45]Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
[46]Jain MK and Ridker PM. Anti-Inflammatory Effects of Statins:Clinical Evidence and Basic Mechanisms. Nat Rev Drug Discov 2005;4:977-87.
[47]Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003;44:2109-19.
[48]Dubuc G, Chamberland A, Wassef H, et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1454-9.
[49]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[50]Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response:the JUPITER Trial. Clinical Chemistry 2012;58:183-9.
[51]Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression:A randomized trial in healthy men. Atherosclerosis 2008; 198:198-207.
[52]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[53]Michelena HI, Osorio LA and Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. International Journal of Cardiology 2005; 101:111-4.
[54]Lambert G, Jarnoux A-L, Pineau T, et al. Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9:Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor. Endocrinology 2006;147:4985-95.
[55]Kourimate S, Le May C, Langhi C, et al. Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Biological Chemistry 2008;283:9666-73.
[56]Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry 2008;54:1038-45.
[57]Chan DC, Hamilton SJ, Rye KA, et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010;12:752-6.
[58]Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008;7:22.
[59]Troutt JS, Alborn WE, Cao G, et al. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. Journal of Lipid Research 2010;51:345-51.
[60]Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010;212:246-51.
[61]Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. Journal of Lipid Research 2007;48:699-708.
[62]Davignon J and Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163-73.
[63]Ason B, Tep S, Davis HR, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of Lipid Research 2011;52:679-87.
[64]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[65]Tremblay AJ, Lamarche B, Lemelin V, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Journal of Lipid Research 2011;52:558-65.
[66]Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009;106:9820-5.
[67]Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels:Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. Journal of the American College of Cardiology 2012;60:1888-98.
[68]Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL):a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet 2012;380:1995-2006.
[69]Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57):a randomised, placebo-controlled, dose-ranging, phase 2 study. The Lancet 2012;380:2007-17.
[70]Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia:the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
[71]Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients:The GAUSS Randomized Trial. JAMA 2012;308:2497-506.
[72]Gusarova V, Howard VG, Okamoto H, et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates. Clinical Lipidology 2012;7:737-43.
[73]Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-18.
[74]McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin. Therapy. Journal of the American College of Cardiology 2012;59:2344-53.
[75]Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
[76]Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900.
[77]Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. Journal of Lipid Research 2012.
[78]Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008;105:11915-20.
[79]Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther 2012;20:376-81.
[80]Du F, Hui Y, Zhang M, et al. Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein. Journal of Biological Chemistry 2011;286:43054-61.
[81]Fattori E, Cappelletti M, Lo Surdo P, et al. Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice. Journal of Lipid Research 2012;53:1654-61.
[82]Tobert JA. Lovastatin and beyond:the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2:517-26.
[83]Learning lessons from Pfizer's$800 million failure. Nat Rev Drug Discov 2011;10:163-4.
[84]Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) TrialA Nested Case-Control Study. Journal of the American College of Cardiology 2012;59:1778-84.
[85]Cariou B, Le Bras M, Langhi C, et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010;211:700-2.
[2]Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1448-53.
[3]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[4]Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response. Arterioscler Thromb Vase Biol 2005;25:2654-60.
[5]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9.
[6]Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
[7]Scartezini M, Hubbart C, Whittall RA, et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clinical Science 2007; 113:435-41.
[8]Huang C-C, Fornage M, Lloyd-Jones DM, et al. Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study. Circulation: Cardiovascular Genetics 2009;2:354-61.
[9]Berge KE, Ose L and Leren TP. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:1094-100. [10] Miyake Y, Kimura R, Kokubo Y, et al. Genetic variants in PCSK9 in the Japanese population:Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008; 196:29-36.
[11]Bourbon M, Alves AC, Medeiros AM, et al. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008; 196:633-42.
[12]Norata GD, Garlaschelli K, Grigore L, et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177-82.
[13]Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007;2:e1043.
[14]Maxwell KN and Breslow JL. Adeno viral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004;101:7100-5.
[15]Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. The Journal of Clinical Investigation 2006; 116:2995-3005.
[16]Zhang D-W, Lagace TA, Garuti R, et al. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry 2007;282:18602-12.
[17]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009;284:1313-23.
[18]Persson L, Cao G, Stahle L, et al. Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2010;32:2666-72.
[19]Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry 2006;281:6211-8.
[20]Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010;213:632-6.
[21]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[22]Libby P, Ridker PM, Hansson GK, et al. Inflammation in Atherosclerosis:From Pathophysiology to Practice. J Am Coll Cardiol 2009;54:2129-38.
[23]Galkina E and Ley K. Immune and Inflammatory Mechanisms of Atherosclerosis*. Annual Review of Immunology 2009;27:165-97.
[24]Gui MH, Hong J, Lu AK, et al. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status. Chin Med J (Engl) 2008; 121:2509-16.
[25]Pacilli A, De Cosmo S, Trischitta V, et al. Role of relationship between HbAlc, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. Atherosclerosis 2013.
[26]Okada K, Furusyo N, Murata M, et al. A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance. Endocrine 2012;41:96-102.
[27]Vaverkova H, Karasek D, Novotny D, et al. Apolipoprotein B versus LDL-cholesterol:Association with other risk factors for atherosclerosis. Clin Biochem 2009;42:1246-51.
[28]Baker RG, Hayden MS and Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22.
[29]Chen XL, Dodd G, Thomas S, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006;290:H1862-70.
[30]He X, Kan H, Cai L, et al. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 2009;46:47-58.
[31]Muthusamy VR, Kannan S, Sadhaasivam K, et al. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med 2012;52:366-76.
[32]Feinberg MW, Lin Z, Fisch S, et al. An Emerging Role for Kruppel-Like Factors in Vascular Biology. Trends in Cardiovascular Medicine 2004; 14:241-6.
[33]SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199:1305-15.
[34]Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proceedings of the National Academy of Sciences 2006;103:6653-8.
[35]Fresco C, Maggioni AP, Signorini S, et al. Variations in lipoprotein levels after myocardial infarction and unstable angina:the LATIN trial. Ital Heart J 2002;3:587-92.
[36]Pitt B, Loscalzo J, Ycas J, et al. Lipid Levels After Acute Coronary Syndromes. Journal of the American College of Cardiology 2008;51:1440-5.
[37]Balci B. The modification of serum lipids after acute coronary syndrome and importance in clinical practice. Curr Cardiol Rev 2011;7:272-6.
[38]Husain M, Armstrong PW, Connelly PW, et al. Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction. Can J Cardiol 1995;11:206-10.
[39]Oliver MF, Kurien VA and Greenwood TW. Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1968;1:710-4.
[40]Kurien VA and Oliver MF. Free fatty acids during acute myocardial infarction. Prog Cardiovasc Dis 1971;13:361-73.
[41]Oliver MF. Free fatty acids and acute coronary syndromes-the history. QJM 2011;104:625-7.
[42]Byrne C, Fitzgerald A, Cannon C, et al. Elevated white cell count in acute coronary syndromes:relationship to variants in inflammatory and thrombotic genes. BMC Medical Genetics 2004;5:13.
[43]Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI16 Investigators. Am J Cardiol 2001;87:636-9, A10.
[44]Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction:a thrornbolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.
[45]Yip HK, Wu CJ, Chang HW, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004;126:1417-22.
[46]Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome:Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. International Journal of Cardiology 2006; 109:248-56.
[47]Yip HK, Hang CL, Fang CY, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005;127:803-8.
[48]Zairis MN, Manousakis SJ, Stefanidis AS, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002;144:782-9.
[49]Thongtang N, Diffenderfer MR, Ooi EM, et al. Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism 2013;62:369-75.
[50]Takahashi T, Hiasa Y, Ohara Y, et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol 2007;100:35-40.
[51]Kaya MG, Akpek M, Lam YY, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention:A prospective, multicenter study. Int J Cardiol 2012.
[52]Bonvini RF, Hendiri T and Camenzind E. Inflammatory response post-myocardial infarction and reperfusion:a new therapeutic target? European Heart Journal Supplements 2005;7:I27-I36.
[53]Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells. Circulation 2005;112:720-6.
[54]Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res 2008;103:690-3.
[55]Lingrel JB, Pilcher-Roberts R, Basford JE, et al. Myeloid-Specific Kruppel-Like Factor 2 Inactivation Increases Macrophage and Neutrophil Adhesion and Promotes Atherosclerosis. Circulation Research 2012;110:1294-302.
[56]Dekker RJ, van Thienen JV, Rohlena J, et al. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005;167:609-18.
[57]van Thienen JV, Fledderus JO, Dekker RJ, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovascular Research 2006;72:231-40.
[58]Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-9.
[59]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009;94:2537-43.
[60]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[61]Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009;55:1637-45.
[62]Cariou B, Le Bras M, Langhi C, et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010;211:700-2.
[63]Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008;54:1038-45.
[64]Mayne J, Raymond A, Chaplin A, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007;361:451-6.
[65]Chan DC, Lambert G, Barrett PH, et al. Plasma proprotein convertase subtilisin/kexin type 9:a marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009;55:2049-52.
[66]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[67]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[68]Miyazawa H, Honda T, Miyauchi S, et al. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta 2012;413:154-9.
[69]Gallin JI, Kaye D and O'Leary WM. Serum lipids in infection. N Engl J Med 1969;281:1081-6.
[70]Kim HL, Jeon HH, Park IY, et al. Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. J Korean Med Sci 2011;26:654-8.
[71]Khovidhunkit W, Kim M-S, Memon RA, et al. Thematic review series:The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. Journal of Lipid Research 2004;45:1169-96.
[72]Dong F, Wang B, Zhang L, et al. Metabolic response to Klebsiella pneumoniae infection in an experimental rat model. PLoS One 2012;7:e51060.
[73]Feingold KR, Moser AH, Shigenaga JK, et al. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008;374:341-4.
[74]Miyazawa H, Tabeta K, Miyauchi S, et al. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice. Lipids Health Dis 2012;11:121.
[75]Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med 2012;30:931-8.
[76]Weber LW, Boll M and Stampfl A. Maintaining cholesterol homeostasis:sterol regulatory element-binding proteins. World J Gastroenterol 2004; 10:3081-7.
[77]Brown MS and Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proceedings of the National Academy of Sciences 1999;96:11041-8.
[78]Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research 2003;44:2109-19.
[79]Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003; 100:12027-32.
[80]Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24:1454-9.
[81]Kourimate S, Le May C, Langhi C, et al. Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Biological Chemistry 2008;283:9666-73.
[82]Espenshade PJ and Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 2007;41:401-27.
[83]Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000; 11 Suppl 16:S140-3.
[84]Pontoglio M, Barra J, Hadchouel M, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84:575-85.
[85]Shih DQ, Bussen M, Sehayek E, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001;27:375-82.
[86]Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to poly genie dyslipidemia. Nat Genet 2009;41:56-65.
[87]Reiner AP, Gross MD, Carlson CS, et al. Common coding variants of the HNF1A gene are associated with multiple cardiovascular risk phenotypes in community-based samples of younger and older European-American adults:the Coronary Artery Risk Development in Young Adults Study and The Cardiovascular Health Study. Circ Cardiovasc Genet 2009;2:244-54.
[88]Pramfalk C, Jiang ZY, Cai Q, et al. HNF1 alpha and SREBP2 are important regulators of NPC1L1 in human liver. J Lipid Res 2010;51:1354-62.
[89]Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95.
[90]Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction-is cholesterol a positive acute phase reactant? Atherosclerosis 1999;142:389-93.
[91]Browning JD and Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010;51:3359-63.
[92]Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
[93]de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
[94]Tsai TT, Nallamothu BK, Mukherjee D, et al. Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein≤80 mg/dl. The American Journal of Cardiology 2005;96:1491-3.
[95]Lee KH, Jeong MH, Kim HM, et al. Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 2011;58:1664-71.
[96]Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) TrialA Nested Case-Control Study. Journal of the American College of Cardiology 2012;59:1778-84.
[1]Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003; 100:928-33.
[2]Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem 2006;98:838-50.
[3]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
[4]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[5]Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-53.
[6]Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants:zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279:48865-75.
[7]Lalanne F, Lambert G, Amar MJ, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005;46:1312-9.
[8]Park SW, Moon YA and Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004;279:50630-8.
[9]Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007;48:1488-98.
[10]Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-12.
[11]McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009;284:10561-70.
[12]Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
[13]Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
[14]O'Keefe JH, Jr., Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl:lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6.
[15]Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160,ⅲ-ⅳ.
[16]Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
[17]Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression:A randomized trial in healthy men. Atherosclerosis 2008; 198:198-207.
[18]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[19]Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response:the JUPITER Trial. Clinical Chemistry 2012;58:183-9.
[20]Michelena HI, Osorio LA and Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol 2005;101:111-4.
[21]Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia:pooled analysis of two phase Ⅱ studies. Clin Ther 2001;23:1209-30.
[22]Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106:1943-8.
[23]Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.
[24]Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
[25]Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53.
[26]Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia:the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464-73.
[27]Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-73.
[28]Liu J, Luo S-H, Qing P, et al. Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro-and anti-inflammatory markers. Clinical Lipidology 2013;8:151-7.
[29]Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6.
[30]Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia:a meta-analysis of randomized controlled trials. Chin Med 2006; 1:4.
[31]Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients:a randomized trial. Ann Intern Med 2009;150:830-9, W147-9.
[32]Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105:198-204.
[33]Venero CV, Venero JV, Wortham DC, et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010;105:664-6.
[34]Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101:1689-93.
[35]Li JJ, Lu ZL, Kou WR, et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009;49:947-56.
[36]Li JJ, Lu ZL, Kou WR, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010;42:231-40.
[37]Shang Q, Liu Z, Chen K, et al. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012;2012:636547.
[38]Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004;24:1454-9.
[39]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[40]Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010;212:246-51.
[41]Dubuc G, Chamberland A, Wassef H, et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1454-9.
[42]Tremblay AJ, Lamarche B, Lemelin V, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Journal of Lipid Research 2011;52:558-65.
[43]Davignon J and Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163-73.
[44]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[45]Ason B, Tep S, Davis HR, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of Lipid Research 2011;52:679-87.
[46]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[47]Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-9.
[48]Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009;284:28885-95.
[49]Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1 alpha and SREBP2:mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51:1486-95.
[50]Toniatti C, Demartis A, Monaci P, et al. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J 1990;9:4467-75.
[51]Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180:3492-501.
[1]Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):Liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences 2003;100:928-33.
[2]Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
[3]Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9):Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008;48:646-54.
[4]Dewpura T, Raymond A, Hamelin J, et al. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS Journal 2008;275:3480-93.
[5]Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A:functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006;281:30561-72.
[6]Zhang D-W, Lagace TA, Garuti R, et al. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry 2007;282:18602-12.
[7]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants. Journal of Biological Chemistry 2009;284:1313-23.
[8]Lo Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011;12:1300-5.
[9]Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. The Journal of Clinical Investigation 2006; 116:2995-3005.
[10]Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences 2008;105:1820-5.
[11]Benjannet S, Luna Saavedra YG, Hamelin J, et al. Effects of the Prosegment and pH on the Activity of PCSK9:EVIDENCE FOR ADDITIONAL PROCESSING EVENTS. Journal of Biological Chemistry 2010;285:40965-78.
[12]Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents. Clinical Chemistry 2009;55:1637-45.
[13]Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010;213:632-6.
[14]Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology & Metabolism 2009;94:2537-43.
[15]Persson L, Cao G, Stahle L, et al. Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2010;32:2666-72.
[16]Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry 2006;281:6211-8.
[17]Rudenko G and Deisenhofer J. The low-density lipoprotein receptor:ligands, debates and lore. Current Opinion in Structural Biology 2003; 13:683-9.
[18]Bottomley MJ, Cirillo A, Orsatti L, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009;284:1313-23.
[19]Pandit S, Wisniewski D, Santoro JC, et al. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. Journal of Lipid Research 2008;49:1333-43.
[20]Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-23.
[21]Cameron J, Holla OL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Human Molecular Genetics 2006; 15:1551-8.
[22]Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1448-53.
[23]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9.
[24]Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response. Arterioscler Thromb Vase Biol 2005;25:2654-60.
[25]Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22.
[26]Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012;223:394-400.
[27]Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
[28]Scartezini M, Hubbart C, Whittall RA, et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clinical Science 2007; 113:435-41.
[29]Bourbon M, Alves AC, Medeiros AM, et al. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008;196:633-42.
[30]Chen SN, Ballantyne CM, Gotto JAM, et al. A Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis. Journal of the American College of Cardiology 2005;45:1611-9.
[31]Hsu LA, Teng MS, Ko YL, et al. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin Chem Lab Med 2009;47:154-8.
[32]Norata GD, Garlaschelli K, Grigore L, et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010;208:177-82.
[33]Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007;2:e1043.
[34]Huang C-C, Fornage M, Lloyd-Jones DM, et al. Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study. Circulation: Cardiovascular Genetics 2009;2:354-61.
[35]Naoumova RP, Tosi I, Patel D, et al. Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene:Long-Term Follow-Up and Treatment Response. Arteriosclerosis, Thrombosis, and Vascular Biology 2005;25:2654-60.
[36]Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk. Journal of Medical Genetics 2006;43:943-9.
[37]Homer VM, Marais AD, Charlton F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008; 196:659-66.
[38]Cameron J, Holla OL, Laerdahl JK, et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. Journal of Internal Medicine 2008;263:420-31.
[39]Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Human Mutation 2005;26:497-.
[40]Essalmani R, Susan-Resiga D, Chamberland A, et al. In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. Journal of Biological Chemistry 2011;286:4257-63.
[41]Pisciotta L, Oliva CP, Cefalu AB, et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006; 186:433-40.
[42]Noguchi T, Katsuda S, Kawashiri M-a, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010;210:166-72.
[43]Berge KE, Ose L and Leren TP. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:1094-100.
[44]Miyake Y, Kimura R, Kokubo Y, et al. Genetic variants in PCSK9 in the Japanese population:Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008;196:29-36.
[45]Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
[46]Jain MK and Ridker PM. Anti-Inflammatory Effects of Statins:Clinical Evidence and Basic Mechanisms. Nat Rev Drug Discov 2005;4:977-87.
[47]Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003;44:2109-19.
[48]Dubuc G, Chamberland A, Wassef H, et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2004;24:1454-9.
[49]Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research 2008;49:394-8.
[50]Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response:the JUPITER Trial. Clinical Chemistry 2012;58:183-9.
[51]Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression:A randomized trial in healthy men. Atherosclerosis 2008; 198:198-207.
[52]Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. Journal of Lipid Research 2010;51:2714-21.
[53]Michelena HI, Osorio LA and Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. International Journal of Cardiology 2005; 101:111-4.
[54]Lambert G, Jarnoux A-L, Pineau T, et al. Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9:Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor. Endocrinology 2006;147:4985-95.
[55]Kourimate S, Le May C, Langhi C, et al. Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Biological Chemistry 2008;283:9666-73.
[56]Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry 2008;54:1038-45.
[57]Chan DC, Hamilton SJ, Rye KA, et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010;12:752-6.
[58]Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008;7:22.
[59]Troutt JS, Alborn WE, Cao G, et al. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. Journal of Lipid Research 2010;51:345-51.
[60]Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010;212:246-51.
[61]Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. Journal of Lipid Research 2007;48:699-708.
[62]Davignon J and Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009;120:163-73.
[63]Ason B, Tep S, Davis HR, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Journal of Lipid Research 2011;52:679-87.
[64]Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9:clinical applications. Journal of Lipid Research 2010;51:140-9.
[65]Tremblay AJ, Lamarche B, Lemelin V, et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. Journal of Lipid Research 2011;52:558-65.
[66]Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009;106:9820-5.
[67]Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels:Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. Journal of the American College of Cardiology 2012;60:1888-98.
[68]Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL):a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet 2012;380:1995-2006.
[69]Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57):a randomised, placebo-controlled, dose-ranging, phase 2 study. The Lancet 2012;380:2007-17.
[70]Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia:the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
[71]Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients:The GAUSS Randomized Trial. JAMA 2012;308:2497-506.
[72]Gusarova V, Howard VG, Okamoto H, et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates. Clinical Lipidology 2012;7:737-43.
[73]Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-18.
[74]McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin. Therapy. Journal of the American College of Cardiology 2012;59:2344-53.
[75]Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
[76]Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900.
[77]Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. Journal of Lipid Research 2012.
[78]Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008;105:11915-20.
[79]Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther 2012;20:376-81.
[80]Du F, Hui Y, Zhang M, et al. Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein. Journal of Biological Chemistry 2011;286:43054-61.
[81]Fattori E, Cappelletti M, Lo Surdo P, et al. Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice. Journal of Lipid Research 2012;53:1654-61.
[82]Tobert JA. Lovastatin and beyond:the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2:517-26.
[83]Learning lessons from Pfizer's$800 million failure. Nat Rev Drug Discov 2011;10:163-4.
[84]Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) TrialA Nested Case-Control Study. Journal of the American College of Cardiology 2012;59:1778-84.
[85]Cariou B, Le Bras M, Langhi C, et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010;211:700-2.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |